INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis
NASDAQ:IPHA • US45781K2042
1.62 USD
-0.09 (-5.54%)
Last: Mar 3, 2026, 03:56 PM
IPHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. IPHA has a bad profitability rating. Also its financial health evaluation is rather negative. IPHA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- IPHA had negative earnings in the past year.
- In the past year IPHA has reported a negative cash flow from operations.
- IPHA had negative earnings in each of the past 5 years.
- IPHA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -49.55%, IPHA perfoms like the industry average, outperforming 50.19% of the companies in the same industry.
- IPHA has a worse Return On Equity (-895.24%) than 79.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| ROIC | N/A |
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 49.52%, IPHA is doing good in the industry, outperforming 75.38% of the companies in the same industry.
- IPHA's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
2. Health
2.1 Basic Checks
- IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- IPHA has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for IPHA has been increased compared to 5 years ago.
- Compared to 1 year ago, IPHA has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -6.50, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
- IPHA has a Altman-Z score of -6.50. This is in the lower half of the industry: IPHA underperforms 64.81% of its industry peers.
- A Debt/Equity ratio of 3.52 is on the high side and indicates that IPHA has dependencies on debt financing.
- IPHA's Debt to Equity ratio of 3.52 is on the low side compared to the rest of the industry. IPHA is outperformed by 80.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.5 |
ROIC/WACCN/A
WACC7.02%
2.3 Liquidity
- IPHA has a Current Ratio of 2.21. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
- IPHA has a Current ratio of 2.21. This is in the lower half of the industry: IPHA underperforms 74.23% of its industry peers.
- IPHA has a Quick Ratio of 2.21. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.21, IPHA is not doing good in the industry: 72.12% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.21 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
- IPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.
- IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.86%.
- IPHA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.80% yearly.
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
3.2 Future
- IPHA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -19.15% yearly.
- Based on estimates for the next years, IPHA will show a very strong growth in Revenue. The Revenue will grow by 41.95% on average per year.
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue Next Year-22.57%
Revenue Next 2Y-12.86%
Revenue Next 3Y-22.02%
Revenue Next 5Y41.95%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
- Also next year IPHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as IPHA's earnings are expected to decrease with -19.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
5. Dividend
5.1 Amount
- No dividends for IPHA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:IPHA (3/3/2026, 3:56:05 PM)
1.62
-0.09 (-5.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-26 2026-03-26/amc
Inst Owners9.46%
Inst Owner Change238.5%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap151.80M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts82.5
Price Target7.41 (357.41%)
Short Float %0.19%
Short Ratio5.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.68%
PT rev (3m)30.64%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)1.64%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)4.93%
Revenue NY rev (3m)4.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 21.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 25.23 | ||
| P/tB | 25.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.07
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.52% | ||
| FCFM | N/A |
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score2
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.52 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.84% | ||
| Cap/Sales | 2.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.21 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | -6.5 |
F-Score2
WACC7.02%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-22.57%
Revenue Next 2Y-12.86%
Revenue Next 3Y-22.02%
Revenue Next 5Y41.95%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.82%
EBIT Next 3Y95.79%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.01%
OCF growth 3YN/A
OCF growth 5YN/A
INNATE PHARMA SA-SPONS ADR / IPHA FAQ
What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IPHA.
Can you provide the valuation status for INNATE PHARMA SA-SPONS ADR?
ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.
What is the profitability of IPHA stock?
INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.
What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?
The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.